Howard Entin
Psychiatry · Centennial, CONPI 1679918882
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 26.3% of the total. Reporting peaked in 2019 at $1,993 and has fallen 52.3% since, to $951 in 2025. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$815
- Neurocrine Biosciences, Inc.$723
- Alkermes, Inc.$719
- Sunovion Pharmaceuticals Inc.$704
- Teva Pharmaceuticals USA, Inc.$560
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,93999%
- Education$1031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $2,377 |
| Lundbeck LLC | 42 | $815 |
| Neurocrine Biosciences, Inc. | 27 | $723 |
| Alkermes, Inc. | 27 | $719 |
| Sunovion Pharmaceuticals Inc. | 33 | $704 |
| Teva Pharmaceuticals USA, Inc. | 24 | $560 |
| Otsuka America Pharmaceutical, Inc. | 26 | $503 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $483 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $470 |
| Vanda Pharmaceuticals Inc. | 11 | $285 |
| Idorsia Pharmaceuticals US Inc | 8 | $251 |
| Avanir Pharmaceuticals, Inc. | 11 | $190 |
| Bausch Health US, LLC | 7 | $146 |
| Merck | 8 | $125 |
| Adlon Therapeutics L.p. | 7 | $122 |
| Corium, LLC | 5 | $120 |
| Johnson & Johnson | 5 | $99 |
| Eisai Inc. | 6 | $94 |
| Shire North American Group Inc | 3 | $60 |
| Neos Therapeutics, LP | 3 | $53 |
| Brainsway USA Inc | 1 | $45 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Neuronetics, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,042 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 19 | $97,296 |
| CaplytaLumateperone Tosylate | 11 | $17,482 |
| VraylarCariprazine Hcl | 11 | $12,522 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,781 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $1,488 |
| Zolpidem Tartrate | 110 | $1,186 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $1,162 |
| Gabapentin | 56 | $881 |
| Clonazepam | 128 | $870 |
| Bupropion Hcl SrBupropion Hcl | 41 | $861 |
| Escitalopram Oxalate | 77 | $655 |
| Lithium Carbonate ErLithium Carbonate | 39 | $630 |
| Bupropion XlBupropion Hcl | 28 | $612 |
| Quetiapine Fumarate | 53 | $560 |
| Lamotrigine | 41 | $440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $560 | $97,29619 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $470 | $17,48211 claims |
| AbbVieVraylar | $2,377 | $12,52211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Centennial
- Brian WiseCentennial$44K
- Robert CowanCentennial$29K
- Thomas VertreesCentennial$3K
- John HardyPueblo$828K
- Larry SandersLittleton$760K
- Jeffrey RichmondDenver$424K
- Jennifer FrenchGlendale$115K
- Charles ParkLone Tree$89K
- Cynthia EppersonAurora$64K
- Brenda CzabanDenver$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.